JW Pharmaceutical Corporation (001065.KS)
KRW 29450.0
(-1.01%)
KRW 29450.0
(-1.01%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 238.91 Billion KRW | 6.1% |
| 2022 | 225.17 Billion KRW | 10.83% |
| 2021 | 203.17 Billion KRW | 13.6% |
| 2020 | 178.84 Billion KRW | -0.71% |
| 2019 | 180.13 Billion KRW | 2.67% |
| 2018 | 175.45 Billion KRW | 5.12% |
| 2017 | 166.91 Billion KRW | 12.17% |
| 2016 | 148.8 Billion KRW | 6.98% |
| 2015 | 139.09 Billion KRW | 4.46% |
| 2014 | 133.16 Billion KRW | 12.3% |
| 2013 | 118.58 Billion KRW | -0.76% |
| 2012 | 119.49 Billion KRW | -9.14% |
| 2011 | 131.51 Billion KRW | -0.62% |
| 2010 | 132.32 Billion KRW | -11.11% |
| 2009 | 148.87 Billion KRW | -3.36% |
| 2008 | 154.04 Billion KRW | 8.71% |
| 2007 | 141.69 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 56.76 Billion KRW | -7.35% |
| 2024 Q2 | 59.47 Billion KRW | 4.78% |
| 2023 Q3 | -55.86 Billion KRW | 11.35% |
| 2023 Q2 | -63.01 Billion KRW | -213.97% |
| 2023 Q1 | 55.29 Billion KRW | -8.3% |
| 2023 FY | 238.91 Billion KRW | 6.1% |
| 2023 Q4 | 61.27 Billion KRW | 209.68% |
| 2022 Q4 | 60.29 Billion KRW | 3.71% |
| 2022 FY | 225.17 Billion KRW | 10.83% |
| 2022 Q1 | 50.96 Billion KRW | -4.38% |
| 2022 Q2 | 55.77 Billion KRW | 9.44% |
| 2022 Q3 | 58.13 Billion KRW | 4.24% |
| 2021 Q1 | 49.54 Billion KRW | 1.0% |
| 2021 Q2 | 53.67 Billion KRW | 8.34% |
| 2021 Q3 | 46.66 Billion KRW | -13.05% |
| 2021 FY | 203.17 Billion KRW | 13.6% |
| 2021 Q4 | 53.29 Billion KRW | 14.22% |
| 2020 Q4 | 49.04 Billion KRW | 17.56% |
| 2020 Q1 | 43.68 Billion KRW | -14.06% |
| 2020 FY | 178.84 Billion KRW | -0.71% |
| 2020 Q3 | 41.72 Billion KRW | -6.01% |
| 2020 Q2 | 44.39 Billion KRW | 1.61% |
| 2019 Q1 | 41.38 Billion KRW | -8.63% |
| 2019 FY | 180.13 Billion KRW | 2.67% |
| 2019 Q2 | 45.82 Billion KRW | 10.72% |
| 2019 Q4 | 50.83 Billion KRW | 20.78% |
| 2019 Q3 | 42.08 Billion KRW | -8.16% |
| 2018 Q4 | 45.29 Billion KRW | 8.52% |
| 2018 Q3 | 41.74 Billion KRW | -8.14% |
| 2018 Q2 | 45.44 Billion KRW | 5.72% |
| 2018 Q1 | 42.98 Billion KRW | -7.71% |
| 2018 FY | 175.45 Billion KRW | 5.12% |
| 2017 Q4 | 46.57 Billion KRW | 13.44% |
| 2017 Q3 | 41.05 Billion KRW | -1.19% |
| 2017 Q2 | 41.54 Billion KRW | 10.07% |
| 2017 Q1 | 37.74 Billion KRW | -0.41% |
| 2017 FY | 166.91 Billion KRW | 12.17% |
| 2016 Q3 | 39.37 Billion KRW | 5.09% |
| 2016 Q2 | 37.46 Billion KRW | 10.01% |
| 2016 Q1 | 34.05 Billion KRW | -9.71% |
| 2016 FY | 148.8 Billion KRW | 6.98% |
| 2016 Q4 | 37.89 Billion KRW | -3.76% |
| 2015 Q1 | 31.33 Billion KRW | -18.72% |
| 2015 Q4 | 37.72 Billion KRW | 5.51% |
| 2015 Q3 | 35.75 Billion KRW | 4.27% |
| 2015 Q2 | 34.28 Billion KRW | 9.41% |
| 2015 FY | 139.09 Billion KRW | 4.46% |
| 2014 FY | 133.16 Billion KRW | 12.3% |
| 2014 Q4 | 38.55 Billion KRW | 14.52% |
| 2014 Q3 | 33.66 Billion KRW | 2.92% |
| 2014 Q2 | 32.71 Billion KRW | 15.92% |
| 2014 Q1 | 28.22 Billion KRW | -11.46% |
| 2013 Q4 | 31.87 Billion KRW | 12.4% |
| 2013 FY | 118.58 Billion KRW | -0.76% |
| 2013 Q1 | 27.26 Billion KRW | -6.6% |
| 2013 Q2 | 31.08 Billion KRW | 14.0% |
| 2013 Q3 | 28.35 Billion KRW | -8.78% |
| 2012 Q4 | 29.19 Billion KRW | -2.09% |
| 2012 FY | 119.49 Billion KRW | -9.14% |
| 2012 Q3 | 29.81 Billion KRW | 0.15% |
| 2012 Q1 | 30.71 Billion KRW | 0.0% |
| 2012 Q2 | 29.77 Billion KRW | -3.06% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 32.36 Billion KRW | 12.51% |
| 2011 Q1 | 28.77 Billion KRW | -15.8% |
| 2011 Q3 | 31.5 Billion KRW | -2.68% |
| 2011 FY | 131.51 Billion KRW | -0.62% |
| 2010 Q4 | 34.16 Billion KRW | 1.16% |
| 2010 FY | 132.32 Billion KRW | -11.11% |
| 2010 Q1 | 32.28 Billion KRW | -10.85% |
| 2010 Q3 | 33.77 Billion KRW | 5.22% |
| 2010 Q2 | 32.09 Billion KRW | -0.58% |
| 2009 Q2 | 36.82 Billion KRW | -4.46% |
| 2009 Q4 | 36.21 Billion KRW | -2.9% |
| 2009 Q3 | 37.29 Billion KRW | 1.29% |
| 2009 Q1 | 38.53 Billion KRW | 1.41% |
| 2009 FY | 148.87 Billion KRW | -3.36% |
| 2008 Q2 | 40.27 Billion KRW | 6.66% |
| 2008 Q3 | 38 Billion KRW | -5.64% |
| 2008 FY | 154.04 Billion KRW | 8.71% |
| 2008 Q4 | 38 Billion KRW | 0.01% |
| 2008 Q1 | 37.76 Billion KRW | -2.33% |
| 2007 Q4 | 38.66 Billion KRW | 5.82% |
| 2007 Q1 | 30.59 Billion KRW | 0.0% |
| 2007 Q2 | 35.9 Billion KRW | 17.36% |
| 2007 FY | 141.69 Billion KRW | 0.0% |
| 2007 Q3 | 36.53 Billion KRW | 1.75% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -405.589% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 19.826% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 14.196% |
| HANDOK Inc. | 153.76 Billion KRW | -55.37% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -245.179% |
| Yuhan Corporation | 489.94 Billion KRW | 51.237% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 22.168% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -471.7% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 60.896% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -231.897% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -37.188% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -496.484% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -155.379% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -108.246% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -405.589% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -462.517% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -218.339% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -307.39% |
| JW Holdings Corporation | 301.25 Billion KRW | 20.695% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 8.448% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 41.538% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -87.132% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -249.74% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -263.354% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | -36.578% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -405.589% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 4.099% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 57.37% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 0.0% |
| Yuhan Corporation | 489.94 Billion KRW | 51.237% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | -23.364% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -243.912% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -326.382% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 0.0% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -89.022% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -102.1% |
| CKD Bio Corp. | 25.19 Billion KRW | -848.218% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | -7.618% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -44.695% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -259.711% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -87.132% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 31.879% |
| Boryung Corporation | 285.16 Billion KRW | 16.219% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -172.91% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -37.188% |
| JW Lifescience Corporation | 20.26 Billion KRW | -1079.132% |